Takeda Pharmaceutical has reached an agreement to buy Shire, capping a monthslong battle for control of the European drugmaker and marking the largest-ever overseas acquisition by a Japanese company.

Takeda said it would buy Shire at £49.01 or $66.56 a share — $30.33 in cash and 0.839 Takeda share for each Shire share — valuing the Dublin-based maker of rare treatments at $62bn. Takeda had until Tuesday to formalize an offer, withdraw it or walk away.